In vivo modeling and molecular characterization: A path toward targeted therapy of melanoma brain metastasis

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Gaziel Sovran, Avital ^a,b   Osman, Iman ^a,b   Hernando, Eva ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Brain metastasis; Brain tropism; Melanoma; Melanoma brain metastasis; Metastasis; Therapy related

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETA CATENIN; CHEMOKINE RECEPTOR CCR4; CLAUDIN 5; CONNEXIN 26; DABRAFENIB; ENDOTHELIN B RECEPTOR; GELATINASE A; HEPARANASE; IPILIMUMAB; JANUS KINASE; MICRORNA 146A; PROTEIN ZO1; STAT PROTEIN; STAT3 PROTEIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; VEMURAFENIB;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; DISEASE CONTROL; DOWNSTREAM PROCESSING; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84887607888     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00127     Document Type: Article

References (59)

1. Agarwala, S. S., Kirkwood, J. M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., et al. (2004). Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 22, 2101-2107. doi:10.1200/JCO.2004.11.044
2. Bos, P. D., Zhang, X. H., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., et al. (2009). Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009. doi:10.1038/nature08021
3. Busch, C., Krochmann, J., and Drews, U. (2012). Human melanoma cells in the rhombencephalon of the chick embryo: a novel model for brain metastasis. Exp. Dermatol. 21, 944-947. doi:10.1111/exd.12041
4. Cruz-Muñoz, W., Jaramillo, M. L., Man, S., Xu, P., Banville, M., Collins, C., et al. (2012). Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res. 72, 4909-4919. doi:10.1158/0008-5472.CAN-12-2194
5. Cruz-Munoz, W., Man, S., Xu, P., and Kerbel, R. S. (2008). Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 68, 4500-4505. doi:10.1158/0008-5472.CAN-08-0041
6. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954. doi:10.1038/nature00766
7. Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W. J., et al. (2011). Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687-1696. doi:10.1002/cncr.25634
8. Eichler, A. F., and Loeffler, J. S. (2007). Multidisciplinary management of brain metastases. Oncologist 12, 884-898. doi:10.1634/theoncologist.12-7-884
9. Ewend, M. G., Carey, L. A., Morris, D. E., Harvey, R. D., and Hensing, T. A. (2001). Brain metastases. Curr. Treat. Options Oncol. 2, 537-547. doi:10.1007/s11864-001-0075-8
10. Fagan, K. A., McMurtry, I. F., and Rodman, D. M. (2001). Role of endothelin-1 in lung disease. Respir. Res. 2, 90-101. doi:10.1186/rr44
11. Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901. doi:10.1016/S0140-6736(12)60398-5
12. Fazakas, C., Wilhelm, I., Nagyoszi, P., Farkas, A. E., Haskó, J., Molnár, J., et al. (2011). Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS ONE 6:e20758. doi:10.1371/journal.pone.0020758
13. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819. doi:10.1056/NEJMoa1002011
14. Fujimaki, T., Price, J. E., Fan, D., Bucana, C. D., Itoh, K., Kirino, T., et al. (1996). Selective growth of human melanoma cells in the brain parenchyma of nude mice. Melanoma Res. 6, 363-371. doi:10.1097/00008390-199610000-00003
15. Gast, A., Scherer, D., Chen, B., Bloethner, S., Melchert, S., Sucker, A., et al. (2010). Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 49, 733-745. doi:10.1002/gcc.20785
16. Herlyn, M., Berking, C., Li, G., and Satyamoorthy, K. (2000). Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res. 10, 303-312. doi:10.1097/00008390-200008000-00001
17. Hodi, F. S., Oble, D. A., Drappatz, J., Velazquez, E. F., Ramaiya, N., Ramakrishna, N., et al. (2008). CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat. Clin. Pract. Oncol. 5, 557-561. doi:10.1038/ncponc1183
18. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723. doi:10.1056/NEJMoa1003466
19. Huang, F. J., Steeg, P. S., Price, J. E., Chiu, W. T., Chou, P. C., Xie, K., et al. (2008). Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res. 68, 9634-9642. doi:10.1158/0008-5472.CAN-08-1429
20. Hwang, S. J., Seol, H. J., Park, Y. M., Kim, K. H., Gorospe, M., Nam, D. H., et al. (2012). MicroRNA-146a suppresses metastatic activity in brain metastasis. Mol. Cells 34, 329-334. doi:10.1007/s10059-012-0171-6
21. Isiklar, I., Leeds, N. E., Fuller, G. N., and Kumar, A. J. (1995). Intracranial metastatic melanoma: correlation between MR imaging characteristics and melanin content. AJR Am. J. Roentgenol. 165, 1503-1512. doi:10.2214/ajr.165.6.7484597
22. Izraely, S., Klein, A., Sagi-Assif, O., Meshel, T., Tsarfaty, G., Hoon, D. S., et al. (2010). Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol. Lett. 130, 107-114. doi:10.1016/j.imlet.2009.12.003
23. Izraely, S., Sagi-Assif, O., Klein, A., Meshel, T., Tsarfaty, G., Pasmanik-Chor, M., et al. (2012). The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int. J. Cancer 131, 1071-1082. doi:10.1002/ijc.27324
24. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972. doi:10.1038/nature09627
25. Johnson, J. D., and Young, B. (1996). Demographics of brain metastasis. Neurosurg. Clin. N. Am. 7, 337-344.
26. Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W. E., Goldbrunner, R., Herms, J., et al. (2010). Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116-122. doi:10.1038/nm.2072
27. Klein, A., Sagi-Assif, O., Izraely, S., Meshel, T., Pasmanik-Chor, M., Nahmias, C., et al. (2012). The metastatic microenvironment: brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells. Int. J. Cancer 131, 2509-2518. doi:10.1002/ijc.27552
28. Küsters, B., de Waal, R. M., Wesseling, P., Verrijp, K., Maass, C., Heerschap, A., et al. (2003). Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res. 63, 5408-5413.
29. Lee, B. C., Lee, T. H., Avraham, S., and Avraham, H. K. (2004). Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol. Cancer Res. 2, 327-338.
30. Lee, I., Fox, P. S., Ferguson, S. D., Bassett, R., Kong, L. Y., Schacherer, C. W., et al. (2012). The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget 3, 336-344.
31. Lin, Q., Balasubramanian, K., Fan, D., Kim, S. J., Guo, L., Wang, H., et al. (2010). Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12, 748-754.
32. Lonser, R. R., Song, D. K., Klapper, J., Hagan, M., Auh, S., Kerr, P. B., et al. (2011). Surgical management of melanoma brain metastases in patients treated with immunotherapy. J. Neurosurg. 115, 30-36. doi:10.3171/2011.3.JNS091107
33. Ma, M. W., Qian, M., Lackaye, D. J., Berman, R. S., Shapiro, R. L., Pavlick, A. C., et al. (2012). Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro-oncology 14, 849-858. doi:10.1093/neuonc/nos113
34. Marchetti, D., Li, J., and Shen, R. (2000). Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Res. 60, 4767-4770.
35. Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465. doi:10.1016/S1470-2045(12)70090-6
36. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., and Chen, L. (2007). Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95-106. doi:10.1038/nrc2051
37. Morsi, A., Gaziel-Sovran, A., Cruz-Munoz, W., Kerbel, R. S., Golfinos, J. G., Hernando, E., et al. (2013). Development and characterization of a clinically relevant mouse model of melanoma brain metastasis. Pigment Cell Melanoma Res. (in press). doi:10.1111/pcmr.12114
38. Murry, B. P., Blust, B. E., Singh, A., Foster, T. P., and Marchetti, D. (2006). Heparanase mechanisms of melanoma metastasis to the brain: development and use of a brain slice model. J. Cell. Biochem. 97, 217-225. doi:10.1002/jcb.20714
39. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977. doi:10.1038/nature09626
40. Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., et al. (2008). TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77. doi:10.1016/j.cell.2008.01.046
41. Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390. doi:10.1038/nature10662
42. Salvati, M., Frati, A., D'Elia, A., Pescatori, L., Piccirilli, M., Pietrantonio, A., et al. (2012). Single brain metastases from melanoma: remarks on a series of 84 patients. Neurosurg. Rev. 35, 211-217. discussion 217-218, doi:10.1007/s10143-011-0348-z
43. Sampson, J. H., Carter, J. H. Jr., Friedman, A. H., and Seigler, H. F. (1998). Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88, 11-20. doi:10.3171/jns.1998.88.1.0011
44. Schartz, N. E., Farges, C., Madelaine, I., Bruzzoni, H., Calvo, F., Hoos, A., et al. (2010). Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res. 20, 247-250. doi:10.1097/CMR.0b013e3283364a37
45. Segura, M. F., Greenwald, H. S., Hanniford, D., Osman, I., and Hernando, E. (2012). MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 33, 1823-1832. doi:10.1093/carcin/bgs205
46. Stoletov, K., Strnadel, J., Zardouzian, E., Momiyama, M., Park, F. D., Kelber, J. A., et al. (2013). Role of connexins in metastatic breast cancer and melanoma brain colonization. J. Cell. Sci. 126(Pt 4), 904-913. doi:10.1242/jcs.112748
47. Straume, O., Smeds, J., Kumar, R., Hemminki, K., and Akslen, L. A. (2002). Significant impact of promoter hypermethylation and the 540 C >T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am. J. Pathol. 161, 229-237. doi:10.1016/S0002-9440(10)64174-0
48. Sundstrøm, T., Daphu, I., Wendelbo, I., Hodneland, E., Lundervold, A., Immervoll, H., et al. (2013). Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a brain metastasis model. Cancer Res. 73, 2445-2456. doi:10.1158/0008-5472.CAN-12-3514
49. Tekle, C., Nygren, M. K., Chen, Y. W., Dybsjord, I., Nesland, J. M., Maelandsmo, G. M., et al. (2012). B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int. J. Cancer 130, 2282-2290. doi:10.1002/ijc.26238
50. Thompson, J. F., Kroon, B. B. R., and Morton, D. L. (2004). Textbook of Melanoma. London: Martin Dunitz.
51. Weiss, L. (1992). Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin. Exp. Metastasis 10, 191-199. doi:10.1007/BF00132751
52. Wilhelm, I., Fazakas, C., and Krizbai, I. A. (2011). In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. (Wars) 71, 113-128.
53. Xie, T. X., Huang, F. J., Aldape, K. D., Kang, S. H., Liu, M., Gershenwald, J. E., et al. (2006). Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 66, 3188-3196. doi:10.1158/0008-5472.CAN-05-2674
54. Yano, S., Shinohara, H., Herbst, R. S., Kuniyasu, H., Bucana, C. D., Ellis, L. M., et al. (2000). Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 60, 4959-4967.
55. Zakrzewski, J., Geraghty, L. N., Rose, A. E., Christos, P. J., Mazumdar, M., Polsky, D., et al. (2011). Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117, 1711-1720. doi:10.1002/cncr.25643
56. Zhang, L., Sullivan, P. S., Goodman, J. C., Gunaratne, P. H., and Marchetti, D. (2011). MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 71, 645-654. doi:10.1158/0008-5472.CAN-10-1910
57. Zhang, X. H., Wang, Q., Gerald, W., Hudis, C. A., Norton, L., Smid, M., et al. (2009a). Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16, 67-78. doi:10.1016/j.ccr.2009.05.017
58. Zhang, C., Zhang, F., Tsan, R., and Fidler, I. J. (2009b). Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res. 69, 828-835. doi:10.1158/0008-5472.CAN-08-2588
59. Zhu, D. Z., Cheng, C. F., and Pauli, B. U. (1991). Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule. Proc. Natl. Acad. Sci. U.S.A. 88, 9568-9572. doi:10.1073/pnas.88.21.9568